In January 2025, Arctic Tx announced the successful closing of a €26.5 million oversubscribed Series A financing from a broad syndicate of international investors. The proceeds from the Series A financing will be used to advance ATx’s two frontrunners, AT-001 and AT-004, further into clinical trials.
In 2024, the European Medicines Agency approved a pivotal phase IIb/III clinical trial evaluating AT-001 for the treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare form of familial dementia. The funding will allow ATx to explore the potential of AT-001, an oral treatment designed to prevent the aggregation of harmful amyloid proteins in the brain, in other forms of familial dementia, and eventually Alzheimer’s disease.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze